Medicinal treatment on symptoms in patients with gastroesophageal reflux disease (GERD) refractory to PPIs. Multicenter, randomized, paralleled controlled study
- Conditions
- Gastroesophageal reflux disease (GERD)
- Registration Number
- JPRN-UMIN000003716
- Lead Sponsor
- Department of Internal Medicine, Saga University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 120
Not provided
1) Patients with GERD which had C or D grade esophagitis diagnosed by endoscopic testing. 2) Patients with serious complications (e.g., hepatic, renal, cardiac, pulmonary, hematological, or metabolic diseases) 3) Patients with abscission of upper gastrointestinal tract 4) Patients who had peptic ulcer (excusing cicatrices) or tumor. 5) Patients with disorder in liver, gallbladder, or pancreas 6) Patients with gastrointestinal bleeding, mechanical ileus, gastrointestinal perforation. 7) Patients who received drugs prohibited for concomitant use during the observation period 8) Patients who were received treatment of rabeprazole (20mg) 9) Patients with psychoneurosis 10) Patients with planning or during treatment of investigational drug 11) Patients with pregnant, considering pregnancy or lactation 12) Patients considered inappropriate by the study investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method